'); jQuery('.cart-remove-box a').on('click', function(){ link = jQuery(this).attr('href'); jQuery.ajax({ url: link, cache: false }); jQuery('.cart-remove-box').remove(); setTimeout(function(){window.location.reload();}, 800); }); }); //jQuery('#ajax_loader').hide(); // clear being added addToCartButton.text(defaultText).removeAttr('disabled').removeClass('disabled'); addToCartButton.parent().find('.disabled-blocker').remove(); loadingDots.remove(); clearInterval(loadingDotId); jQuery('body').append(""); setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); }); } try { jQuery.ajax( { url : url, dataType : 'json', type : 'post', data : data, complete: function(){ if(jQuery('body').hasClass('product-edit') || jQuery('body').hasClass('wishlist-index-configure')){ jQuery.ajax({ url: "https://www.stemcell.com/meigeeactions/updatecart/", cache: false }).done(function(html){ jQuery('header#header .top-cart').replaceWith(html); }); jQuery('#ajax_loader').hide(); jQuery('body').append(""); setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); } }, success : function(data) { if(data.status == 'ERROR'){ jQuery('body').append(''); }else{ ajaxComplete(); } } }); } catch (e) { } // End of our new ajax code this.form.action = oldUrl; if (e) { throw e; } } }.bind(productAddToCartForm); productAddToCartForm.submitLight = function(button, url){ if(this.validator) { var nv = Validation.methods; delete Validation.methods['required-entry']; delete Validation.methods['validate-one-required']; delete Validation.methods['validate-one-required-by-name']; if (this.validator.validate()) { if (url) { this.form.action = url; } this.form.submit(); } Object.extend(Validation.methods, nv); } }.bind(productAddToCartForm); function setAjaxData(data,iframe,name,image){ if(data.status == 'ERROR'){ jQuery('body').append(''); }else{ if(data.sidebar && !iframe){ if(jQuery('.top-cart').length){ jQuery('.top-cart').replaceWith(data.sidebar); } if(jQuery('.sidebar .block.block-cart').length){ if(jQuery('#cart-sidebar').length){ jQuery('#cart-sidebar').html(jQuery(data.sidebar).find('#mini-cart')); jQuery('.sidebar .block.block-cart .subtotal').html(jQuery(data.sidebar).find('.subtotal')); }else{ jQuery('.sidebar .block.block-cart p.empty').remove(); content = jQuery('.sidebar .block.block-cart .block-content'); jQuery('').appendTo(content); jQuery('').appendTo(content); content.find('#cart-sidebar').html(jQuery(data.sidebar).find('#mini-cart').html()); content.find('.actions').append(jQuery(data.sidebar).find('.subtotal')); content.find('.actions').append(jQuery(data.sidebar).find('.actions button.button')); } cartProductRemove('#cart-sidebar li.item a.btn-remove', { confirm: 'Are you sure you would like to remove this item from the shopping cart?', submit: 'Ok', calcel: 'Cancel' }); } jQuery.fancybox.close(); jQuery('body').append(''); }else{ jQuery.ajax({ url: "https://www.stemcell.com/meigeeactions/updatecart/", cache: false }).done(function(html){ jQuery('header#header .top-cart').replaceWith(html); jQuery('.top-cart #mini-cart li.item a.btn-remove').on('click', function(event){ event.preventDefault(); jQuery('body').append('Are you sure you would like to remove this item from the shopping cart?OkCancel'); jQuery('.cart-remove-box a').on('click', function(){ link = jQuery(this).attr('href'); jQuery.ajax({ url: link, cache: false }); jQuery('.cart-remove-box').remove(); setTimeout(function(){window.location.reload();}, 800); }); }); jQuery.fancybox.close(); jQuery('body').append(''); }); } } setTimeout(function () {jQuery('.add-to-cart-success').slideUp(500)}, 5000); } // The EasySep Human CD4+ T Cell Enrichment Kit is designed to isolate CD4+ T cells from fresh or previously frozen peripheral mononuclear cells by negative selection. Unwanted cells are targeted for removal with Tetrameric Antibody Complexes recognizing non-CD4+ T cells and dextran-coated magnetic particles. Labeled cells are separated using an EasySep magnet without the use of columns. Desired cells are poured off into a new tube.
For even faster cell isolations, we recommend the new EasySep Human CD4+ T Cell Isolation Kit (17952) which isolates cells in just 8 minutes.
Advantages:
Fast, easy-to-use and column-free Up to 97% purity Untouched, viable cells
Magnet Compatibility:
EasySep Magnet (Catalog #18000)
The Big Easy EasySep Magnet (Catalog #18001)
Easy 50 EasySep Magnet (Catalog #18002)
EasyPlate EasySep Magnet (Catalog 18102)
EasyEights EasySep Magnet (Catalog #18103)
RoboSep-S (Catalog #21000)
Subtype:
Cell Isolation Kits
Cell Type:
T Cells; T Cells, CD4+
Sample Source:
Leukapheresis; PBMC
Selection Method:
Negative
Application:
Cell Isolation
Area of Interest:
Immunology
Document Type
Product Name
Catalog #
Lot #
Language
Yes. The EasySep kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).
Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.
The EasySep procedure is column-free. That's right - no columns!
The Product Information Sheet provided with each EasySep kit contains detailed staining information.
Yes. RoboSep, the fully automated cell separator, automates all EasySep labeling and cell separation steps.
Yes. We recommend a cell concentration of 2x108 cells/mL and a minimum working volume of 100 L. Samples containing 2x107 cells or fewer should be suspended in 100 L of buffer.
Yes, the EasySep particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.
No, but due to the small size of these particles, they will not interfere with downstream applications.
Yes; however, this may impact the kit's performance. The provided EasySep protocols have already been optimized to balance purity, recovery and time spent on the isolation.
Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.
If particle binding is a key concern, we offer two options for negative selection. The EasySep negative selection kits can isolate untouched cells with comparable purities, while RosetteSep can isolate untouched cells directly from whole blood without using particles or magnets.
Read More
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Research Area Workflow Stages for
Workflow Stages
Figure 1. FACS Histogram Results Using EasySep Human CD4+ T Cell Enrichment Kit
Starting with frozen mononuclear cells, the CD4+ T cell content of the enriched fraction typically ranges from 92% - 97%.
Huang S-H et al.
The presence of persistent, latent HIV reservoirs in CD4+ T cells obstructs current efforts to cure infection. The so-called kick-and-kill paradigm proposes to purge these reservoirs by combining latency-reversing agents with immune effectors such as cytotoxic T lymphocytes. Support for this approach is largely based on success in latency models, which do not fully reflect the makeup of latent reservoirs in individuals on long-term antiretroviral therapy (ART). Recent studies have shown that CD8+ T cells have the potential to recognize defective proviruses, which comprise the vast majority of all infected cells, and that the proviral landscape can be shaped over time due to in vivo clonal expansion of infected CD4+ T cells. Here, we have shown that treating CD4+ T cells from ART-treated individuals with combinations of potent latency-reversing agents and autologous CD8+ T cells consistently reduced cell-associated HIV DNA, but failed to deplete replication-competent virus. These CD8+ T cells recognized and potently eliminated CD4+ T cells that were newly infected with autologous reservoir virus, ruling out a role for both immune escape and CD8+ T cell dysfunction. Thus, our results suggest that cells harboring replication-competent HIV possess an inherent resistance to CD8+ T cells that may need to be addressed to cure infection.
Albert BJ et al.
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through the administration of synergistic combinations of latency reversing agents (LRAs), such as histone deacetylase (HDAC) inhibitors and protein kinase C (PKC) modulators, provides a promising strategy to reduce if not eradicate the viral reservoir. Here, we demonstrate that largazole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs. Significantly, these isoform-targeted HDAC inhibitors synergize with PKC modulators, namely bryostatin-1 analogues (bryologs). Implementation of this unprecedented LRA combination induces HIV-1 reactivation to unparalleled levels and avoids global T-cell activation within resting CD4+ T-cells.
Hultquist JF et al.
New genetic tools are needed to understand the functional interactions between HIV and human host factors in primary cells. We recently developed a method to edit the genome of primary CD4(+) T cells by electroporation of CRISPR/Cas9 ribonucleoproteins (RNPs). Here, we adapted this methodology to a high-throughput platform for the efficient, arrayed editing of candidate host factors. CXCR4 or CCR5 knockout cells generated with this method are resistant to HIV infection in a tropism-dependent manner, whereas knockout of LEDGF or TNPO3 results in a tropism-independent reduction in infection. CRISPR/Cas9 RNPs can furthermore edit multiple genes simultaneously, enabling studies of interactions among multiple host and viral factors. Finally, in an arrayed screen of 45 genes associated with HIV integrase, we identified several candidate dependency/restriction factors, demonstrating the power of this approach as a discovery platform. This technology should accelerate target validation for pharmaceutical and cell-based therapies to cure HIV infection.
Vanwalscappel B et al.
Treatment of HIV-infected patients with IFN- results in significant, but clinically insufficient, reductions of viremia. IFN induces the expression of several antiviral proteins including BST-2, which inhibits HIV by multiple mechanisms. The viral protein Vpu counteracts different effects of BST-2. We thus asked if Vpu proteins from IFN-treated patients displayed improved anti-BST-2 activities as compared to Vpu from baseline. Deep-sequencing analyses revealed that in five of seven patients treated by IFN- for a concomitant HCV infection in the absence of antiretroviral drugs, the dominant Vpu sequences differed before and during treatment. In three patients, vpu alleles that emerged during treatment improved virus replication in the presence of IFN-, and two of them conferred improved virus budding from cells expressing BST-2. Differences were observed for the ability to down-regulate CD4, while all Vpu variants potently down-modulated BST-2 from the cell surface. This report discloses relevant consequences of IFN-treatment on HIV properties.
Hrecka K et al.
HIV replication in nondividing host cells occurs in the presence of high concentrations of noncanonical dUTP, apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3 (APOBEC3) cytidine deaminases, and SAMHD1 (a cell cycle-regulated dNTP triphosphohydrolase) dNTPase, which maintains low concentrations of canonical dNTPs in these cells. These conditions favor the introduction of marks of DNA damage into viral cDNA, and thereby prime it for processing by DNA repair enzymes. Accessory protein Vpr, found in all primate lentiviruses, and its HIV-2/simian immunodeficiency virus (SIV) SIVsm paralogue Vpx, hijack the CRL4(DCAF1) E3 ubiquitin ligase to alleviate some of these conditions, but the extent of their interactions with DNA repair proteins has not been thoroughly characterized. Here, we identify HLTF, a postreplication DNA repair helicase, as a common target of HIV-1/SIVcpz Vpr proteins. We show that HIV-1 Vpr reprograms CRL4(DCAF1) E3 to direct HLTF for proteasome-dependent degradation independent from previously reported Vpr interactions with base excision repair enzyme uracil DNA glycosylase (UNG2) and crossover junction endonuclease MUS81, which Vpr also directs for degradation via CRL4(DCAF1) E3. Thus, separate functions of HIV-1 Vpr usurp CRL4(DCAF1) E3 to remove key enzymes in three DNA repair pathways. In contrast, we find that HIV-2 Vpr is unable to efficiently program HLTF or UNG2 for degradation. Our findings reveal complex interactions between HIV-1 and the DNA repair machinery, suggesting that DNA repair plays important roles in the HIV-1 life cycle. The divergent interactions of HIV-1 and HIV-2 with DNA repair enzymes and SAMHD1 imply that these viruses use different strategies to guard their genomes and facilitate their replication in the host.
STEMCELL TECHNOLOGIES INC.S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.
Internal Search Keywords: 19052|19052RF|19052C.2|19012|14052 |Easy sep CD-4 T|Easy sep CD4|CD4+ T cell isolation|CD4 T cell isolation|T cell isolation
Go here to see the original:
EasySep Human CD4+ T Cell Enrichment Kit
- 001 Strange lesions after stem-cell therapy [Last Updated On: June 25th, 2010] [Originally Added On: June 25th, 2010]
- 002 Pat McCrory will do the right thing. He supports non-embryonic stem cell research. - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 003 The potential of stem cells.flv - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- 004 StemEnhance is the Biggest Scientific Medical breakthrough of our time - World Exclusive! - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 005 Hiv Positive Man Cured - Video [Last Updated On: October 16th, 2011] [Originally Added On: October 16th, 2011]
- 006 Invitrx "Reluma" with Habib Torfi - Video [Last Updated On: October 17th, 2011] [Originally Added On: October 17th, 2011]
- 007 Negative Campaign against Bonnie Marge Westerford - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 008 HIV Resistant Genes...Rhesus Negative, Excess PK [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 009 Insidermedicine in 60 - December 7, 2007 - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 010 Stem Cell Therapy - BioLogic Anti-Aging Skin Cream - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 011 Stem Cell Research (Government Hilbrands) - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 012 Stem Cell News ISCO.MP4 - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 013 N5-FG-108-all_30fps.AVI - Video [Last Updated On: October 20th, 2011] [Originally Added On: October 20th, 2011]
- 014 Stem cell [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- 015 Steam Cell Reasearch - Video [Last Updated On: October 24th, 2011] [Originally Added On: October 24th, 2011]
- 016 Meat from a petri dish may be on the menu soon :oP - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- 017 Mmmm meat from a petri dish may be on the menu soon - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- 018 Parents of a CP Girl - Talk about Stem Cell Treatment Experience (2) - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- 019 George Somlo, MD - What is triple negative breast cancer? | City of Hope - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- 020 Stem Enhance - Stem Cell Enhancer - Video [Last Updated On: October 28th, 2011] [Originally Added On: October 28th, 2011]
- 021 VistaGen's Cardiac OrganDots(TM) Produced for Drug Rescue - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- 022 The Power of Stem Cells - Video [Last Updated On: November 10th, 2011] [Originally Added On: November 10th, 2011]
- 023 Adult stem cell treatment, quality and testing - Video [Last Updated On: November 26th, 2011] [Originally Added On: November 26th, 2011]
- 024 Cord Blood Stem Cell Transfusion Saves 3-Year-Old Child - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 025 Dr. Uma Lakshimipathy presents Generation of Transgene-Free Induced Pluripotent Stem Cells - Video [Last Updated On: December 28th, 2011] [Originally Added On: December 28th, 2011]
- 026 StemFlo - Blood Circulation Enhancer, Antioxidant and More!.flv - Video [Last Updated On: January 1st, 2012] [Originally Added On: January 1st, 2012]
- 027 Dr Tony Talebi discusses treatment of multiple myeloma patients with Dr Ratzan - Video [Last Updated On: January 2nd, 2012] [Originally Added On: January 2nd, 2012]
- 028 Dr Tony Talebi discusses stem cell transplantation in Myeloma with Dr Ratzan - Video [Last Updated On: January 2nd, 2012] [Originally Added On: January 2nd, 2012]
- 029 Frank Young Joins Bioheart as Financial Consultant [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 030 Scientists use old theory to discover new targets in fight against breast cancer [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 031 Salk Scientists Use an Old Theory to Discover New Targets in the Fight Against Breast Cancer [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]
- 032 Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 033 Bioheart to Present at BioFlorida's Saturday Exchange [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 034 Nasal Stem Cells Show Promise in Repairing Spinal Cord Damage Caused by Contusion [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- 035 Gentium Responds to the EMA's Day 120 List of Questions for Defibrotide MAA [Last Updated On: February 22nd, 2012] [Originally Added On: February 22nd, 2012]
- 036 Bone Marrow Prolotherapy at Caring Medical - Dr. Ross Hauser - Video [Last Updated On: February 23rd, 2012] [Originally Added On: February 23rd, 2012]
- 037 Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call [Last Updated On: February 25th, 2012] [Originally Added On: February 25th, 2012]
- 038 Mass. General researchers isolate egg-producing stem cells from adult human ovaries [Last Updated On: February 27th, 2012] [Originally Added On: February 27th, 2012]
- 039 The Lancet Publishes Results from Gentium's Phase III Defibrotide Trial for the Prevention of VOD in Paediatric Patients [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- 040 Egg-producing stem cells isolated from adult human ovaries [Last Updated On: February 28th, 2012] [Originally Added On: February 28th, 2012]
- 041 This is the only time bad breath is a good thing [Last Updated On: March 1st, 2012] [Originally Added On: March 1st, 2012]
- 042 BGI Demos Single-Cell Exome Sequencing Method on Tumor Cell Lines, Patient Samples [Last Updated On: March 7th, 2012] [Originally Added On: March 7th, 2012]
- 043 Cancer Paradigm Shift: Biomarker Links Clinical Outcome with New Model of Lethal Tumor Metabolism [Last Updated On: March 15th, 2012] [Originally Added On: March 15th, 2012]
- 044 NCCN Presents New Guidelines for Acute Lymphoblastic Leukemia [Last Updated On: March 21st, 2012] [Originally Added On: March 21st, 2012]
- 045 Bioheart Labs and Stemlogix Veterinary Products Featured in Media [Last Updated On: March 23rd, 2012] [Originally Added On: March 23rd, 2012]
- 046 ImmunoCellular Therapeutics to Present on Cancer Stem Cell Targeting at the AACR Annual Meeting [Last Updated On: March 27th, 2012] [Originally Added On: March 27th, 2012]
- 047 Are Cancer Stem Cells Ready for Prime Time? [Last Updated On: April 1st, 2012] [Originally Added On: April 1st, 2012]
- 048 Bacterin International Holdings, Inc. Schedules First Quarter 2012 Financial Earnings Conference Call [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 049 Apple to the Rescue [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 050 Bacterin Secures Accounts Receivable Credit Facility [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 051 Gentium Receives Day 180 List of Outstanding Issues From the CHMP for Defibrotide MAA [Last Updated On: May 4th, 2012] [Originally Added On: May 4th, 2012]
- 052 Stem cell shield may protect body from chemotherapy side effects [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 053 Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 054 Gene-modified stem cell transplant protects patients from toxic side effects of chemotherapy, study suggests [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 055 Stem cell jab cuts chemo side effects [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 056 Boston scientists grow lung tissue from cystic fibrosis patients’ skin cells [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 057 New England Journal of Medicine Reports on Three Phase III REVLIMID® (lenalidomide) Trials in Patients with Newly ... [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 058 Transplanted Gene-Modified Blood Stem Cells Protect Brain Cancer Patients From Toxic Side Effects of Chemotherapy [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 059 Stem cells jab 'helps brain cancer patients tolerate chemotherapy' [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 060 'Cell shield' for cancer patients [Last Updated On: May 11th, 2012] [Originally Added On: May 11th, 2012]
- 061 Researchers find a way to delay aging of stem cells [Last Updated On: May 25th, 2012] [Originally Added On: May 25th, 2012]
- 062 Method to delay aging of stem cells developed [Last Updated On: May 25th, 2012] [Originally Added On: May 25th, 2012]
- 063 Verastem to Present Scientific Data at the 2012 ASCO Annual Meeting [Last Updated On: May 29th, 2012] [Originally Added On: May 29th, 2012]
- 064 Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved [Last Updated On: May 31st, 2012] [Originally Added On: May 31st, 2012]
- 065 Breast stem cell research: Receptor teamwork required and a new pathway may be involved [Last Updated On: May 31st, 2012] [Originally Added On: May 31st, 2012]
- 066 This Week in Pathology [Last Updated On: June 1st, 2012] [Originally Added On: June 1st, 2012]
- 067 China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012 [Last Updated On: June 12th, 2012] [Originally Added On: June 12th, 2012]
- 068 Cryo-Save Group N.V: Further cost savings with closure of France [Last Updated On: June 14th, 2012] [Originally Added On: June 14th, 2012]
- 069 Cell Therapeutics Appoints New Chief Medical Officer [Last Updated On: June 14th, 2012] [Originally Added On: June 14th, 2012]
- 070 Gentium Submits Day 180 Response to List of Outstanding Issues Received From the EMA's CHMP for Defibrotide MAA [Last Updated On: June 21st, 2012] [Originally Added On: June 21st, 2012]
- 071 Bioheart's Chief Science Officer Kristin Comella Presents at 10th Annual Meeting of International Society for Stem ... [Last Updated On: June 25th, 2012] [Originally Added On: June 25th, 2012]
- 072 Bioheart Announces New Brand Image, Launches Redesigned Website and New Company Logo [Last Updated On: June 27th, 2012] [Originally Added On: June 27th, 2012]
- 073 Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of ... [Last Updated On: July 4th, 2012] [Originally Added On: July 4th, 2012]
- 074 Scientists Find New Way to Up Safety Factor of Stem Cell Therapy by Causing Contaminated Cells to Purge Themselves [Last Updated On: October 1st, 2012] [Originally Added On: October 1st, 2012]
- 075 Arlen Specter praised as fighter from a more moderate era [Last Updated On: October 15th, 2012] [Originally Added On: October 15th, 2012]
- 076 Nanodiamond coating for a better Petri dish [Last Updated On: October 16th, 2012] [Originally Added On: October 16th, 2012]
- 077 Bioheart Extends Licenses of Electrical Stimulation Patents With Airspeed [Last Updated On: October 18th, 2012] [Originally Added On: October 18th, 2012]
- 078 Stem Cells Therapy [Last Updated On: May 19th, 2015] [Originally Added On: May 19th, 2015]
- 079 Stem Cell Research - Stem Cell Treatments - Treatments ... [Last Updated On: May 19th, 2015] [Originally Added On: May 19th, 2015]
- 080 5. Hematopoietic Stem Cells [Stem Cell Information] [Last Updated On: May 24th, 2015] [Originally Added On: May 24th, 2015]